475 related articles for article (PubMed ID: 25052345)
1. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
4. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
Belle A; Baumann C; Bigard MA; Zallot C; Gizard E; Guéant JL; Bronowicki JP; Peyrin-Biroulet L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):877-81. PubMed ID: 26121376
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
6. Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
Waszczuk E; Waszczuk KM; Mulak A; Paradowski L
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):628-32. PubMed ID: 26904976
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.
Chevaux JB; Nani A; Oussalah A; Venard V; Bensenane M; Belle A; Gueant JL; Bigard MA; Bronowicki JP; Peyrin-Biroulet L
Inflamm Bowel Dis; 2010 Jun; 16(6):916-24. PubMed ID: 19885908
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease.
Gisbert JP; Villagrasa JR; Rodríguez-Nogueiras A; Chaparro M
Am J Gastroenterol; 2012 Oct; 107(10):1460-6. PubMed ID: 23034605
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply.
Zheng X; Ye X; Du P; Zeng J; Zhu W; Yang B; Li C; Allain JP
Transfusion; 2015 Apr; 55(4):890-7. PubMed ID: 25363504
[TBL] [Abstract][Full Text] [Related]
11. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis.
Navarro R; Concha-Garzón MJ; Castaño C; Casal C; Guiu A; Daudén E
Int J Dermatol; 2014 Jul; 53(7):909-11. PubMed ID: 24673290
[TBL] [Abstract][Full Text] [Related]
14. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan.
Su FH; Bai CH; Chu FY; Lin YS; Su CT; Yeh CC
Vaccine; 2012 Jun; 30(27):4034-9. PubMed ID: 22531558
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
Spaan M; Bruce M; Agarwal K; Carey I
Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
[TBL] [Abstract][Full Text] [Related]
16. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Zanetti AR; Mariano A; Romanò L; D'Amelio R; Chironna M; Coppola RC; Cuccia M; Mangione R; Marrone F; Negrone FS; Parlato A; Zamparo E; Zotti C; Stroffolini T; Mele A;
Lancet; 2005 Oct 15-21; 366(9494):1379-84. PubMed ID: 16226616
[TBL] [Abstract][Full Text] [Related]
17. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India.
Sukriti ; Pati NT; Sethi A; Agrawal K; Agrawal K; Kumar GT; Kumar M; Kaanan AT; Sarin SK
J Gastroenterol Hepatol; 2008 Nov; 23(11):1710-5. PubMed ID: 18761556
[TBL] [Abstract][Full Text] [Related]
18. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.
Gisbert JP; Menchén L; García-Sánchez V; Marín I; Villagrasa JR; Chaparro M
Aliment Pharmacol Ther; 2012 Jun; 35(12):1379-85. PubMed ID: 22530631
[TBL] [Abstract][Full Text] [Related]
20. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
Knöll A; Boehm S; Hahn J; Holler E; Jilg W
J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
